Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation

Chemotherapy plus bevacizumab is currently considered as the standard 1st line treatment of advanced colorectal cancer (ACC). Whereas GI perforation is a known side effect of bevacizumab, the development of GI ulcers has not been reported. We identified 18 patients with ACC who participated in a pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Tol, J., Cats, A., Mol, L., Koopman, M., Bos, M. M. E. M., van der Hoeven, J. J. M., Antonini, N. F., van Krieken, J. H. J. M., Punt, C. J. A.
Formato: Texto
Lenguaje:English
Publicado: Springer US 2008
Materias:
Phase III Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2480515/
https://www.ncbi.nlm.nih.gov/pubmed/18335169
http://dx.doi.org/10.1007/s10637-008-9125-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2480515/
https://www.ncbi.nlm.nih.gov/pubmed/18335169
http://dx.doi.org/10.1007/s10637-008-9125-4

Ejemplares similares